<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39380062</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>SSRI use during acute COVID-19 and risk of long COVID among patients with depression.</ArticleTitle><Pagination><StartPage>445</StartPage><MedlinePgn>445</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">445</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-024-03655-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Long COVID, also known as post-acute sequelae of COVID-19 (PASC), is a poorly understood condition with symptoms across a range of biological domains that often have debilitating consequences. Some have recently suggested that lingering SARS-CoV-2 virus&#xa0;particles in the gut may impede serotonin production and that low serotonin may drive many Long COVID symptoms across a range of biological systems. Therefore, selective serotonin reuptake inhibitors (SSRIs), which increase synaptic serotonin availability, may be used to prevent or treat Long COVID. SSRIs are commonly prescribed for depression, therefore restricting a study sample to only include patients with depression can reduce the concern of confounding by indication.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In an observational sample of electronic health records from patients in the National COVID Cohort Collaborative (N3C) with a COVID-19 diagnosis between September 1, 2021, and December 1, 2022, and a comorbid depressive disorder, the leading indication for SSRI use, we evaluated the relationship between SSRI use during acute COVID-19 and subsequent 12-month risk of Long COVID (defined by ICD-10 code U09.9). We defined SSRI use as a prescription for SSRI medication beginning at least 30&#xa0;days before acute COVID-19 and not ending before SARS-CoV-2 infection. To minimize bias, we estimated relationships using nonparametric targeted maximum likelihood estimation to aggressively adjust for high-dimensional covariates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We analyzed a sample (n&#x2009;=&#x2009;302,626) of patients with a diagnosis of a depressive condition before COVID-19 diagnosis, where 100,803 (33%) were using an SSRI. We found that SSRI users had a significantly lower risk of Long COVID compared to nonusers (adjusted causal relative risk 0.92, 95% CI (0.86, 0.99)) and we found a similar relationship comparing new SSRI users (first SSRI prescription 1 to 4&#xa0;months before acute COVID-19 with no prior history of SSRI use) to nonusers (adjusted causal relative risk 0.89, 95% CI (0.80, 0.98)).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings suggest that SSRI use during acute COVID-19 may be protective against Long COVID, supporting the hypothesis that serotonin may be a key mechanistic biomarker of Long COVID.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Butzin-Dozier</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-6419-0008</Identifier><AffiliationInfo><Affiliation>School of Public Health, University of California, Berkeley, Berkeley, CA, USA. zbutzin@berkeley.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Yunwen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Public Health, University of California, Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deshpande</LastName><ForeName>Sarang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Public Health, University of California, Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurwitz</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anzalone</LastName><ForeName>A Jerrod</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coyle</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Public Health, University of California, Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Junming</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Public Health, University of California, Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mertens</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Public Health, University of California, Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Laan</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>School of Public Health, University of California, Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colford</LastName><ForeName>John M</ForeName><Initials>JM</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>School of Public Health, University of California, Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Rena C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hubbard</LastName><ForeName>Alan E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>School of Public Health, University of California, Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>National COVID Cohort Collaborative (N3C) Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 GM104938</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002649</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001433</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001422</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001860</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001427</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104942</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001420</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001439</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002243</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001445</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003096</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002537</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001412</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001872</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001878</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002529</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002494</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002736</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115516</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002369</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002541</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115371</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002001</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002538</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115458</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001442</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002535</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001866</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003167</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001409</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001449</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001453</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002489</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104940</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003107</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>INV-018455</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003015</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002733</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002003</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001876</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001436</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002378</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002384</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002553</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002389</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001414</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104941</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002014</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002550</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002319</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001855</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001425</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002373</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002240</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002556</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003017</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001998</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001881</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002645</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002366</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115428</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002377</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115677</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002544</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003098</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001430</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003142</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Selective Serotonin Reuptake Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="Y">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">SSRI</Keyword></KeywordList><CoiStatement>The authors declare no competing interests related to this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>23</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39380062</ArticleId><ArticleId IdType="pmc">PMC11462648</ArticleId><ArticleId IdType="doi">10.1186/s12916-024-03655-x</ArticleId><ArticleId IdType="pii">10.1186/s12916-024-03655-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Robertson MM, Qasmieh SA, Kulkarni SG, Teasdale CA, Jones HE, McNairy M, et al. The epidemiology of long coronavirus disease in US adults. Clin Infect Dis. 2023;76(9):1636&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">36542514</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: an overview. Diab Metab Syndr. 2021;15(3):869&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AC, Devason AS, Umana IC, Cox TO, Dohnalov&#xe1; L, Litichevskiy L, et al. Serotonin reduction in post-acute sequelae of viral infection. Cell. 2023. Available from: 10.1016/j.cell.2023.09.013. Cited 2023 Oct 19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11227373</ArticleId><ArticleId IdType="pubmed">37848036</ArticleId></ArticleIdList></Reference><Reference><Citation>Belluck P. Scientists offer a new explanation for long COVID. The New York Times. 2023. Available from: https://www.nytimes.com/2023/10/16/health/long-covid-serotonin.html.</Citation></Reference><Reference><Citation>Reese JT, Blau H, Casiraghi E, Bergquist T, Loomba JJ, Callahan TJ, et al. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. eBioMedicine. 2023;87:104413 Available from: https://linkinghub.elsevier.com/retrieve/pii/S2352396422005953.. Cited 2023 Oct 26
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9769411</ArticleId><ArticleId IdType="pubmed">36563487</ArticleId></ArticleIdList></Reference><Reference><Citation>Created with Biorender.com. 2024. Available from: &#x200d; https://biorender.com.
</Citation></Reference><Reference><Citation>Chu A, Wadhwa R. Selective serotonin reuptake inhibitors. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available from: http://www.ncbi.nlm.nih.gov/books/NBK554406/. Cited 2023 Nov 29.</Citation><ArticleIdList><ArticleId IdType="pubmed">32119293</ArticleId></ArticleIdList></Reference><Reference><Citation>Preskorn S. Clinical pharmacology of serotonin selective reuptake inhibitors. Caddo: Professional Communications; 1996.</Citation></Reference><Reference><Citation>Reis G, Dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10(1):e42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8550952</ArticleId><ArticleId IdType="pubmed">34717820</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Buse JB, Liebovitz DM, Nicklas JM, Puskarich MA, Cohen K, et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023;23(10):1119&#x2013;29 Available from: https://linkinghub.elsevier.com/retrieve/pii/S1473309923002992. Cited 2023 Oct 13. Cited 2023 Oct 13
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Foletto VS, da Rosa TF, Serafin MB, H&#xf6;rner R. Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use. Eur J Clin Pharmacol. 2022;78(10):1601&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9360648</ArticleId><ArticleId IdType="pubmed">35943535</ArticleId></ArticleIdList></Reference><Reference><Citation>Stingl JC. Antidepressant drug treatment protecting from COVID-19: one more piece in the repurposing puzzle. BJPsych Open. 2021;8(1):e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8692840</ArticleId><ArticleId IdType="pubmed">34924095</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidky H, Sahner DK, Girvin AT, Hotaling N, Michael SG, Gersing K. Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19. medRxiv&#x202f;: the preprint server for health sciences. United States; 2023. p. 2022.11.09.22282142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10839808</ArticleId><ArticleId IdType="pubmed">38318198</ArticleId></ArticleIdList></Reference><Reference><Citation>Slurink IAL, van den Houdt SCM, Mertens G. Who develops long COVID? Longitudinal pre-pandemic predictors of long COVID and symptom clusters in a representative Dutch population. Int J Infect Dis. 2024;10(144):107048.</Citation><ArticleIdList><ArticleId IdType="pubmed">38609036</ArticleId></ArticleIdList></Reference><Reference><Citation>Rus CP, de Vries BEK, de Vries IEJ, Nutma I, Kooij JJS. Treatment of 95 post-COVID patients with SSRIs. Sci Rep. 2023;13(1):18599 10.1038/s41598-023-45072-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10622561</ArticleId><ArticleId IdType="pubmed">37919310</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunham KE, Venton BJ. SSRI antidepressants differentially modulate serotonin reuptake and release in Drosophila. J Neurochem. 2022;162(5):404&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9427694</ArticleId><ArticleId IdType="pubmed">35736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K. Overview of the potential use of fluvoxamine for COVID-19 and long COVID. Discov Ment Health. 2023;3(1):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10029802</ArticleId><ArticleId IdType="pubmed">36968793</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Laan MJ, Rose S. Targeted learning: causal inference for observational and experimental data. New York: Springer; 2011. p. 626 Springer series in statistics.</Citation></Reference><Reference><Citation>van der Laan M, Coyle J, Hejazi N, Malenica I, Phillips R, Hubbard A. Targeted learning in R: causal data science with the tlverse software ecosystem. 2023. Available from: https://tlverse.org/tlverse-handbook/optimal-individualized-treatment-regimes.html.</Citation></Reference><Reference><Citation>National center for advancing translational sciences. N3C dashboards. 2023. Available from: https://covid.cd2h.org/dashboard/.</Citation></Reference><Reference><Citation>Coyle JR, Hejazi NS, Malenica I, Phillips RV, Arnold BF, Mertens A, et al. Targeted learning. In: Wiley StatsRef: Statistics Reference Online. 2023:1&#x2013;20. Available from: 10.1002/9781118445112.stat08414. Cited 2023 May 17.</Citation></Reference><Reference><Citation>Van der Laan MJ, Rose S. Targeted learning in data science: causal inference for complex longitudinal studies. New York, NY: Springer Berlin Heidelberg; 2017.</Citation></Reference><Reference><Citation>Gruber S, Lee H, Phillips R, Ho M, van der Laan M. Developing a targeted learning-based statistical analysis plan. Stat Biopharmaceut Res. 2022;23:1&#x2013;8. 10.1080/19466315.2022.2116104.</Citation></Reference><Reference><Citation>ICD10 Data. 2023 ICD-10-CM diagnosis code U09.9. ICD10data.com. 2023. Available from: https://www.icd10data.com/ICD10CM/Codes/U00-U85/U00-U49/U09-/U09.9. Cited 2023 Sep 12. </Citation></Reference><Reference><Citation>Applicable Data Methods &amp; Standards Domain Team. N3C concept set - 38249145 (depression). 2024 Jan 30. Available from: https://zenodo.org/doi/10.5281/zenodo.7685710. Cited 2024 May 14.
</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.7685710</ArticleId></ArticleIdList></Reference><Reference><Citation>Beasley W. Phenotype data acquisition. Github; Available from: https://github.com/National-COVID-Cohort-Collaborative/Phenotype_Data_Acquisition/wiki/Latest-Phenotype.
</Citation></Reference><Reference><Citation>McGrath LJ, Scott AM, Surinach A, Chambers R, Benigno M, Malhotra D. Use of the postacute sequelae of COVID-19 diagnosis code in routine clinical practice in the US. JAMA Netw Open. 2022;5(10):e2235089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9539719</ArticleId><ArticleId IdType="pubmed">36201207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zachary Butzin-Dozier, Yunwen Ji, Haodong Li, Jeremy Coyle, Junming (Seraphina) Shi, Rachael V. Philips, et al. Predicting long COVID in the National COVID Cohort Collaborative using super learner. medRxiv. 2023;2023.07.27.23293272. Available from: http://medrxiv.org/content/early/2023/08/04/2023.07.27.23293272.abstract.
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11364083</ArticleId><ArticleId IdType="pubmed">39146534</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Laan M. Why we need a statistical revolution. Sense about Science USA. 2015. Available from: https://senseaboutscienceusa.org/super-learning-and-the-revolution-in-knowledge/.</Citation></Reference><Reference><Citation>van der Laan MJ, Polley EC, Hubbard AE. Super learner. Stat Appl Genet Mol Biol. 2007;6:Article25.</Citation><ArticleIdList><ArticleId IdType="pubmed">17910531</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips RV, van der Laan MJ, Lee H, Gruber S. Practical considerations for specifying a super learner. Int J Epidemiol. 2023:dyad023. Available from: 10.1093/ije/dyad023 . Cited 2023 Jun 15.</Citation><ArticleIdList><ArticleId IdType="pubmed">36905602</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz Munoz I, van der Laan MJ. Sensitivity analysis for causal inference under unmeasured confounding and measurement error problems. Division of Biostatistics, UC Berkeley; 2012. http://www.bepress.com/ucbbiostat/paper303.
</Citation><ArticleIdList><ArticleId IdType="pubmed">24246288</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassett AL, Radvanski DC, Buyske S, Savage SV, Sigal LH. Psychiatric comorbidity and other psychological factors in patients with &#x201c;chronic Lyme disease.&#x201d; Am J Med. 2009;122(9):843&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2751626</ArticleId><ArticleId IdType="pubmed">19699380</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassett AL, Radvanski DC, Buyske S, Savage SV, Gara M, Escobar JI, et al. Role of psychiatric comorbidity in chronic Lyme disease. Arthritis Care Res. 2008;59(12):1742&#x2013;9. 10.1002/art.24314. Cited 2024 May 9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19035409</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Zhao J, Fan X, Guo W. Dysfunction in serotonergic and noradrenergic systems and somatic symptoms in psychiatric disorders. Front Psychiatry. 2019;10: 286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6537908</ArticleId><ArticleId IdType="pubmed">31178761</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensler JG, Artigas F, Bortolozzi A, Daws LC, De Deurwaerd&#xe8;re P, Milan L, et al. Catecholamine/serotonin interactions: systems thinking for brain function and disease. Adv Pharmacol. 2013;68:167&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3902978</ArticleId><ArticleId IdType="pubmed">24054145</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansari ME, Manta S, Oosterhof C, El Iskandrani KS, Chenu F, Shim S, et al. Restoration of serotonin neuronal firing following long-term administration of bupropion but not paroxetine in olfactory bulbectomized rats. Int J Neuropsychopharmacol. 2015;18(4):pyu050. 10.1093/ijnp/pyu050. Cited 2024 May 14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4360219</ArticleId><ArticleId IdType="pubmed">25522394</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn A, Lanzenberger R, Wadsak W, Spindelegger C, Moser U, Mien LK, et al. Escitalopram enhances the association of serotonin-1A autoreceptors to heteroreceptors in anxiety disorders. J Neurosci. 2010;30(43):14482&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6634816</ArticleId><ArticleId IdType="pubmed">20980606</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal C, Herzog C, Haeberle AM, Bombarde C, Miquel MC, Carimalo J, et al. Early dysfunction of central 5-HT system in a murine model of bovine spongiform encephalopathy. Neuroscience. 2009;160(4):731&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">19285121</ArticleId></ArticleIdList></Reference><Reference><Citation>Wielpuetz C, Kuepper Y, Grant P, Munk AJL, Hennig J. Acute responsivity of the serotonergic system to S-citalopram and positive emotionality-the moderating role of the 5-HTTLPR. Front Hum Neurosci. 2013;7:486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3750213</ArticleId><ArticleId IdType="pubmed">23986679</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery SA, Kasper S, Stein DJ, Bang Hedegaard K, Lemming OM. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2001;16(2):75&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">11236072</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry. 2002;63(9):796&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">12363120</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamijima K, Murasaki M, Asai M, Higuchi T, Nakajima T, Taga C, et al. Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients. Psychiatry Clin Neurosci. 2004;58(4):427&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">15298657</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkhamees AA. Obsessive-compulsive disorder post-COVID-19: a case presentation. Egypt J Neurol Psychiatr Neurosurg. 2021;57(1):150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8557101</ArticleId><ArticleId IdType="pubmed">34744416</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuler MS, Rose S. Targeted maximum likelihood estimation for causal inference in observational studies. Am J Epidemiol. 2017;185(1):65&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">27941068</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaff ER, Girvin AT, Bennett TD, Bhatia A, Brooks IM, Deer RR, et al. Identifying who has long COVID in the USA: a machine learning approach using N3C data. Lancet Digit Health. 2022;4(7):e532&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110014</ArticleId><ArticleId IdType="pubmed">35589549</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen DG (Din), Sun J, Peace KE, editors. Interval-censored time-to-event data: methods and applications. 0 ed. Chapman and Hall/CRC; 2012. Available from: https://www.taylorfrancis.com/books/9781466504288. Cited 2024 Jan 10. 
</Citation></Reference><Reference><Citation>Pfaff ER, Madlock-Brown C, Baratta JM, Bhatia A, Davis H, Girvin A, et al. Coding long COVID: characterizing a new disease through an ICD-10 lens. BMC Med. 2023;21(1):58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9931566</ArticleId><ArticleId IdType="pubmed">36793086</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>